170 related articles for article (PubMed ID: 3519413)
1. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Karaiskos C; Raptis S
Horm Metab Res; 1986 Apr; 18(4):253-5. PubMed ID: 3519413
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
Hasegawa T; Yoneda M; Nakamura K; Ohnishi K; Harada H; Kyouda T; Yoshida Y; Makino I
J Gastroenterol Hepatol; 1998 Dec; 13(12):1201-6. PubMed ID: 9918426
[TBL] [Abstract][Full Text] [Related]
3. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
[TBL] [Abstract][Full Text] [Related]
4. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
Hayakawa T; Noda A; Kondo T; Okumura N
Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
[No Abstract] [Full Text] [Related]
5. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
6. [Modification of carbohydrate metabolism and oral glucose tolerance test in type II diabetics using the glucosidase inhibitor acarbose].
Schwartzkopff W; Calder D
Med Welt; 1984 Feb; 35(6):169-74. PubMed ID: 6369065
[No Abstract] [Full Text] [Related]
7. Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs.
Robertson J; Nelson R; Kass P; Neal L
Am J Vet Res; 1999 May; 60(5):541-5. PubMed ID: 10328421
[TBL] [Abstract][Full Text] [Related]
8. The mechanism of alpha-glucosidase inhibition in the management of diabetes.
Bischoff H
Clin Invest Med; 1995 Aug; 18(4):303-11. PubMed ID: 8549017
[TBL] [Abstract][Full Text] [Related]
9. [Inhibition of intestinal alpha glucosidases in the therapy of diabetes mellitus].
Fölsch UR; Lembcke B
Internist (Berl); 1991 Dec; 32(12):699-707. PubMed ID: 1823561
[No Abstract] [Full Text] [Related]
10. Therapeutic potential of alpha-glucosidase-inhibitors.
Fölsch UR
Hepatogastroenterology; 1982 Apr; 29(2):47-8. PubMed ID: 7044933
[No Abstract] [Full Text] [Related]
11. Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats.
Yamamoto M; Otsuki M
Metabolism; 2006 Apr; 55(4):533-40. PubMed ID: 16546485
[TBL] [Abstract][Full Text] [Related]
12. alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
Dimitriadis GD; Tessari P; Go VL; Gerich JE
Metabolism; 1985 Mar; 34(3):261-5. PubMed ID: 3883097
[TBL] [Abstract][Full Text] [Related]
13. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
Ledermann H; Höxter G
Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
[TBL] [Abstract][Full Text] [Related]
14. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
[TBL] [Abstract][Full Text] [Related]
15. [Acarbose--a new therapeutic principle in diabetes mellitus therapy].
Schöffling K; Hillebrand I
Dtsch Med Wochenschr; 1981 Aug; 106(35):1083-4. PubMed ID: 6114844
[No Abstract] [Full Text] [Related]
16. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of acarbose as monotherapy in NIDDM patients.
Deerochanawong C; Serirat S; Kornthong P
J Med Assoc Thai; 1996 Feb; 79(2):69-75. PubMed ID: 8868016
[TBL] [Abstract][Full Text] [Related]
18. Effects of an alpha-glucosidase inhibitor, acarbose, on blood glucose and serum lipids in streptozotocin-induced diabetic rats.
Yamashita K; Sugawara S; Sakairi I
Horm Metab Res; 1984 Apr; 16(4):179-82. PubMed ID: 6373545
[TBL] [Abstract][Full Text] [Related]
19. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
20. [Acarbose, an unduly neglected antidiabetic drug].
Iványi J; Gyimesi A
Orv Hetil; 1996 Dec; 137(49):2737-41. PubMed ID: 9679608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]